scholarly journals Continuous hemadsorption with cytokine adsorber for severe COVID-19: A case series of 15 patients

2021 ◽  
pp. 039139882110237
Author(s):  
Christopher Paisey ◽  
Chinmay Patvardhan ◽  
Michael Mackay ◽  
Alain Vuylsteke ◽  
Sai Kiran Bhagra
Keyword(s):  
Potential Role ◽  
Case Series ◽  
Post Treatment ◽  
Inflammatory Biomarkers ◽  
Adjunctive Treatment ◽  
Cytokine Storm ◽  
Cytokine Release ◽  
Tnf Α ◽  
Significant Difference ◽  
D Dimer

Background: Hyperinflammation and cytokine release has been associated with severe Covid-19. Hemadsorption cartridges may have a potential role in treatment of cytokine storm associated with the development of severe Covid-19. Methods: We retrospectively examined the case records of patients with severe Covid-19 receiving adjunctive hemadsorption (HA) in our ICU. We analyzed inflammatory biomarkers pre- and post- HA. Results: Fifteen patients received HA during the study period. All were intubated, ventilated and required renal replacement therapy. 11/15 were supported on ECMO. Mean ferritin 2652 (±3286) ng/ml, mean CRP 154 (±92) mg/ml, median D-dimer 3071 (±2689) ng/ml, mean troponin 236 (±461) ng/L. We found significant difference in pre-and post- treatment ferritin 3622 ng/ml versus 1682 ng/ml ( p = 0.022), CRP 222 mg/ml versus 103 mg/ml ( p = 0.008, 95% CI 22.4–126.5), lactate 2 mmol/L versus 1.3 mmol/L ( p = 0.017), and procalcitonin 15.3 ng/ml versus 4.2 ng/ml ( p = 0.023). No significant difference in pre- and post- treatment IL-6 14 pg/ml versus 43 pg/ml ( p = 0.32), IL-10 3.4 pg/ml versus 2.6 pg/ml ( p = 0.31), IL1 β 0.37 pg/ml versus 0.77 pg/ml ( p = 0.75), TNF α 12.77 pg/ml versus 12.49 pg/ml ( p = 0.75), VIS 10.04 versus 6.01 ( p = 0.31, 95% CI 5.98–17.16) was seen. Conclusions: The use of HA as adjunctive treatment in a critically unwell group of COVID-19 patients lead to a reduction in ferritin, CRP, procalcitonin and lactate with no significant change in other parameters. The use of HA in the treatment of severe COVID-19 requires further larger randomized studies.

scholarly journals Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1067
Author(s):  
Oleksandr Oliynyk ◽  
Wojciech Barg ◽  
Anna Slifirczyk ◽  
Yanina Oliynyk ◽  
Vitaliy Gurianov ◽  
...  
Keyword(s):  
Macrophage Activation Syndrome ◽  
Macrophage Activation ◽  
Cytokine Storm ◽  
Cytokine Release ◽  
Cytokine Release Syndrome ◽  
C Reactive Protein ◽  
Treatment Results ◽  
Reactive Protein ◽  
Median Serum ◽  
D Dimer

Background: Cytokine storm in COVID-19 is heterogenous. There are at least three subtypes: cytokine release syndrome (CRS), macrophage activation syndrome (MAS), and sepsis. Methods: A retrospective study comprising 276 patients with SARS-CoV-2 pneumonia. All patients were tested for ferritin, interleukin-6, D-Dimer, fibrinogen, calcitonin, and C-reactive protein. According to the diagnostic criteria, three groups of patients with different subtypes of cytokine storm syndrome were identified: MAS, CRS or sepsis. In the MAS and CRS groups, treatment results were assessed depending on whether or not tocilizumab was used. Results: MAS was diagnosed in 9.1% of the patients examined, CRS in 81.8%, and sepsis in 9.1%. Median serum ferritin in patients with MAS was significantly higher (5894 vs. 984 vs. 957 ng/mL, p < 0.001) than in those with CRS or sepsis. Hypofibrinogenemia and pancytopenia were also observed in MAS patients. In CRS patients, a higher mortality rate was observed among those who received tocilizumab, 21 vs. 10 patients (p = 0.043), RR = 2.1 (95% CI 1.0–4.3). In MAS patients, tocilizumab decreased the mortality, 13 vs. 6 patients (p = 0.013), RR = 0.50 (95% CI 0.25–0.99). Сonclusions: Tocilizumab therapy in patients with COVID-19 and CRS was associated with increased mortality, while in MAS patients, it contributed to reduced mortality.

scholarly journals Probable Neuropsychological & Cognitive Complications due to Cytokine Storm in Patients With COVID-19

2021 ◽  
Vol 0 (0) ◽  
pp. 1-37
Author(s):  
Zahra Keshtgar ◽  
◽  
GH. Reza Chalabianloo ◽  
Niloofar Esmaeili ◽  
◽  
...  
Keyword(s):  
Nervous System ◽  
Case Reports ◽  
Case Series ◽  
Executive Dysfunction ◽  
Inflammatory Factors ◽  
Cytokine Storm ◽  
Case Control Studies ◽  
Necrosis Factor Alpha ◽  
Cross Sectional ◽  
Tnf Α

Introduction: COVID-19 (coronavirus disease 2019) was identified in China in December 2019 for the first time and is rapidly spreading throughout the world as a pandemic. As COVID-19 causes mild to severe acute respiratory syndrome, most studies in this context have focused on pathogenesis primarily in the respiratory system. However, evidence shows that the central nervous system (CNS) may also be affected by COVID-19. Since COVID-19 is spreading, it is imperative to study its possible cognitive effects in patients suffering and recovering from COVID-19. Methods: The articles used in this study were searched by keywords such as Cytokine storm and covid-19, covid-19 and executive dysfunction, cognitive disorder and covid-19, CNS and covid 19, Coronavirus, Neuroinvasion in science direct, Scopus, PubMed, Embase, and Web of Science databases based on Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) checklist. The study will assess all observational studies published between December 2019 and April 2021 in peer-reviewed journals, including cross-sectional, cohort, case-control studies, case reports and case series. The search result was 106 articles, of which 73 articles related to Covid-19, the stages of infection by this virus, its effect on the nervous system and neurological symptoms, the cytokine storm caused by this infection, and the possible cognitive consequences caused by this virus in patients, has been reviewed. Other articles were not checked due to their limited relevance to the topic under discussion. Results: Studies show that neurons may be directly affected by SARS-CoV-1 and SARS-CoV-2. Furthermore, various studies indicate that systemic inflammation (so-called "cytokine storm") is also responsible for brain damage induced by infection with SARS-CoV-1 and SARS-CoV-2. Such a way that this patients showed elevated levels of interleukin (IL-), 6, 8, and 10 and of tumor necrosis factor-alpha (TNF- α) in their blood. Conclusion: Various cognitive defects following an increase level of cytokines such as TNF-α and IL-6,8 have been observed. Therefore, due to the increase level of these pro-inflammatory factors in the brains of these patients, cognitive deficits can be expected, which need further investigation.

scholarly journals The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients

2021 ◽  
Vol 27 ◽  
pp. 107602962110503
Author(s):  
Mark Jaradeh ◽  
Nausheen Baig ◽  
Emily Bontekoe ◽  
Mirjana Mitrovic ◽  
Darko Antic ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Factor Xiii ◽  
Plasminogen Activator Inhibitor ◽  
Inflammatory Biomarkers ◽  
Kinetic Assay ◽  
Blood Profile ◽  
Inflammatory Biomarker ◽  
Tnf Α ◽  
Pai 1 ◽  
D Dimer

Introduction Thrombo-inflammatory biomarkers play an important role in the pathogenesis of lymphoma. We aimed to characterize the interrelationship of thrombo-inflammatory biomarkers and blood cellular indices in lymphoma patients. Materials and Methods Ninety-eight lymphoma patient samples were collected from Lymphoma Center of Clinic of Hematology, University of Belgrade, Serbia. Normal controls (n = 50) represented plasma from healthy individuals. Plasminogen activator inhibitor (PAI-1), D-Dimer, factor XIII, C-reactive protein (CRP), microparticles (Mp), Von Willebrand factor (vWF), total protein S, urokinase-type plasminogen activator (uPA), tumor necrosis factor (TNF α), β2-glycoprotein I ( β2GPI), and fibronectin levels were measured utilizing commercially-available ELISA methods. Thrombin generation profile (TGA) was measured using a fluorometric kinetic assay. Platelets, leukocytes, lymphocytes, and neutrophils were measured in conjunction with the complete blood profile. Results Statistically significant differences were noted in levels of PAI-1, D-Dimer, factor XIII, CRP, microparticles, vWF, uPA, TNF α, β2GPI, fibronectin, and TGA when compared to normal (all P values < .001). Platelet to leukocyte ratio (PLA) correlated to TNF α and fibronectin ( R = −0.31 and −0.53, respectively) and the platelet to neutrophil ratio (PNR) correlated to factor XIII and β2GPI ( R = 0.40 and 0.40, respectively). Conclusion Plasma samples from lymphoma patients demonstrated a significantly altered thrombo-inflammatory biomarker profile that has notable correlations to blood cellular indices.

scholarly journals EXTRACORPOREAL SHOCKWAVE THERAPY IN SHOULDER INJURIES: PROSPECTIVE STUDY

2021 ◽  
Vol 29 (5) ◽  
pp. 268-273
Author(s):  
VICTOR OTAVIO MORAES DE OLIVEIRA ◽  
JULIANA MUNHOZ VERGARA ◽  
VICENTE FURQUIM DE OLIVEIRA ◽  
PAULO HENRIQUE SCHMIDT LARA ◽  
LUIZ CARLOS NOGUEIRA JÚNIOR ◽  
...  
Keyword(s):  
Rotator Cuff ◽  
Range Of Motion ◽  
Case Series ◽  
Post Treatment ◽  
Dash Score ◽  
Extracorporeal Shockwave Therapy ◽  
Extracorporeal Shockwave ◽  
Shockwave Therapy ◽  
Significant Difference ◽  
Functional Scores

ABSTRACT Objective: To evaluate the functional results after the use of extracorporeal shockwave therapy (ESWT) in four groups of patients: tendinopathy, partial rotator cuff injury, adhesive capsulitis and calcareous tendinopathy of the rotator cuff at one month and three months after the end of treatment. Methods: Case series in which patients were evaluated according to the VAS of pain, range of motion of the shoulder, and functional questionnaires DASH and modified UCLA. Results: There was a significant increase in the measure of flexion, lateral rotation and shoulder abduction in the evaluations after treatment in relation to the baseline measurement (p < 0.001) and no evidence of significant difference was found between the post-treatment evaluations at one month and three months follow-up (p > 0.05). There was a significant reduction in the VAS score, increase in the UCLA score and a significant reduction in the DASH score in the post-treatment evaluations in relation to the baseline score (p < 0.001) and a significant improvement in the three-month evaluation in relation to one month (p < 0.05). Conclusion: Extracorporeal shockwave therapy proved to be efficient and safe in the treatment of shoulder pathologies, improving pain, range of motion and functional scores in all groups of patients evaluated in the study. Level of Evidence IV, Case series.

scholarly journals MO968ROUTINE BIOMARKERS FOR THE SEVERITY OF COVID-19 PNEUMONIA MAY PRESENT DIFFERENTLY IN KIDNEY TRANSPLANT RECIPIENTS

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Elena Burgos García ◽  
Maria Molina Gomez ◽  
Judit Cacho ◽  
Francisco Javier Juega Mariã‘o ◽  
Laura Cañas Sole ◽  
...  
Keyword(s):  
Clinical Presentation ◽  
Ferritin Level ◽  
Clinical Status ◽  
Inflammatory Biomarkers ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Inflammatory Parameters ◽  
Significant Difference ◽  
D Dimer ◽  
Comparative Activity

Abstract Background and Aims The treatment of coronavirus disease (COVID-19) is based on the patient’s clinical status and levels of inflammatory biomarkers. The comparative activity of these biomarkers in KT patients with COVID-19 pneumonia from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and non-SARS-CoV-2 aetiologies is unknown. The aim of this study was to compare the clinical presentation and inflammatory parameters at admission of KT patients with COVID-19 pneumonia and those with non-COVID-19 pneumonia over the same period. Method Biomarkers were measured and compared between KT patients with COVID-19 pneumonia (n=42) and non-COVID-19 pneumonia (n=18) from March to November 2020. Results Both groups showed comparable demographics. The COVID-19 KT patients had fewer neutrophils (4,650 [2,925-9,498] vs. 9,100 [7,170-11,150],p=0.01) than the non-COVID group, although there was no significant difference in the lymphocyte count. Non-COVID-19 pneumonia was associated with a higher d-dimer (962 [427-1,448] vs. 1,704 [868-2,481],p=0.09) and IL-6 (37 [23-10] vs 254 [53-602],p=0.006) levels. The ferritin level was higher in the COVID-19 group (908 [496-1,377] vs. 340 [264-785],p=0.008). Conclusion COVID-19 pneumonia in KT recipients shows a different presentation of inflammatory biomarkers than other non-COVID pneumonias. It could be usefully to identify KT patients with COVID-19.More detailed studies are necessary to understand the presentation of biomarkers in KT with COVID-19.

scholarly journals Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 228
Author(s):  
Agung Putra ◽  
Agus Widyatmoko ◽  
Sugeng Ibrahim ◽  
Fajar Amansyah ◽  
Farid Amansyah ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Case Series ◽  
Cytokine Storm ◽  
Blood Gas ◽  
C Reactive Protein ◽  
Severe Condition ◽  
Reactive Protein ◽  
D Dimer

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the outbreak of coronavirus disease 2019 (COVID-19), which has been rapidly spreading. Several guideline therapies have been proposed as a possible treatment for SARS-CoV-2, however, these therapies are not sufficient to treat a severe condition of SARS-CoV-2 infection characterised by the increase of D-dimer and C-reactive protein (CRP) levels, and patchy ground-glass opacities (GGOs). Secretome-mesenchymal stem cells (S-MSCs) produced by MSCs under hypoxia could excessively release several anti-inflammatory cytokines and growth factors to control the COVID-19 cytokine storm and accelerate lung injury improvement. This is the first study investigating the clinical outcomes of three severe COVID-19 patients admitted to the intensive care unit of three different hospitals in Indonesia treated with S-MSCs. The decrease of D-dimer and CRP level was reported for all patients treated with S-MSCs. This was in line with improvement of pulmonary radiology, blood gas level, and hematologic assessment. In conclusion, these cases suggest that S-MSCs could effectively control D-dimer, CRP level and GGOs of severe COVID-19 patients associated with recovered pulmonary function.

scholarly journals Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 228
Author(s):  
Agung Putra ◽  
Agus Widyatmoko ◽  
Sugeng Ibrahim ◽  
Fajar Amansyah ◽  
Farid Amansyah ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Case Series ◽  
Cytokine Storm ◽  
Blood Gas ◽  
C Reactive Protein ◽  
Severe Condition ◽  
Reactive Protein ◽  
D Dimer

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the outbreak of coronavirus disease 2019 (COVID-19), which has been rapidly spreading. Several guideline therapies have been proposed as a possible treatment for SARS-CoV-2, however, these therapies are not sufficient to treat a severe condition of SARS-CoV-2 infection characterised by the increase of D-dimer and C-reactive protein (CRP) levels, and patchy ground-glass opacities (GGOs). Secretome-mesenchymal stem cells (S-MSCs) produced by MSCs under hypoxia could excessively release several anti-inflammatory cytokines and growth factors to control the COVID-19 cytokine storm and accelerate lung injury improvement. This is the first study investigating the clinical outcomes of three severe COVID-19 patients admitted to the intensive care unit of three different hospitals in Indonesia treated with S-MSCs. The decrease of D-dimer and CRP level was reported for all patients treated with S-MSCs. This was in line with improvement of pulmonary radiology, blood gas level, and hematologic assessment. In conclusion, these cases suggest that S-MSCs could effectively control D-dimer, CRP level and GGOs of severe COVID-19 patients associated with recovered pulmonary function.

Abstract TP454: Hemostatic Biomarkers Succeed While Inflammatory Biomarkers Fail To Differentiate Vascular Dementia From Alzheimer’S Disease

Stroke ◽  
2016 ◽  
Vol 47 (suppl_1) ◽  
Author(s):  
Venugopalan Y Vishnu ◽  
Manish Modi ◽  
Vivek K Garg ◽  
Manju Mohanty ◽  
Manoj K Goyal ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Fdg Pet ◽  
Plasma Fibrinogen ◽  
Inflammatory Biomarkers ◽  
Csf Biomarkers ◽  
Significant Difference ◽  
Biomarker Analysis ◽  
D Dimer

Introduction: A reliable plasma biomarker in differentiating between Alzheimer’s disease (AD) and Vascular dementia (VaD) is the need of the hour, in most memory clinics. Hypothesis: We assessed the hypothesis that plasma inflammatory [Interleukin 6 (IL 6) and C-Reactive Protein (CRP)] and hemostatic (Fibrinogen and D dimer) biomarkers can aid in differentiating between AD and VaD. Methods: Neuropsychological assessment, MRI brain, FDG-PET brain and CSF biomarkers of AD (Aβ42 and total tau) were used for establishing the diagnosis of Mild Cognitive Impairment (MCI), AD or VaD. ELISA analyses for IL6, Fibrinogen, D dimer and CRP were performed according to the manufacturers’ protocols. Results: During the study period (January 2013-April 2014), 68 diagnosed patients of AD/MCI/VaD were included. FDG PET brain, plasma fibrinogen, D dimer, IL6 and CRP were done in all 68 patients while 48 patients underwent CSF biomarker analysis. Sixteen patients had MCI, of which 11 were MCI-AD and 5 were MCI-VaSC. There were 41 patients with AD (Mild AD- 9, Mod AD -23, Severe AD- 9) and 11 patients with VaD. The Alzheimer group (MCI-AD and AD) and Vascular group (MCI VaSC & VaD) consisted of 52 and 16 patients respectively. Table 1 depicts biomarker levels. Alzheimer and Vascular groups did not exhibit significant difference in IL6 and CRP levels. Plasma fibrinogen levels were significantly higher in VaD and vascular group as compared to Alzheimer group. But MCI-VaSC was not significantly different from MCI-AD. Plasma D dimer levels were significantly higher in all vascular subgroups compared to Alzheimer subgroups except between MCI-VaSC and MCI-AD. Conclusion: In conclusion, hemostatic biomarkers (Plasma Fibrinogen and D dimer) succeed, whereas inflammatory biomarkers (IL6 and CRP) fail in differentiating VaD from AD.

scholarly journals Laboratory abnormalities in children with refractory mycoplasma pneumoniae pneumonia: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Zhili Wang ◽  
Yu He ◽  
zhengxiu luo
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Clinical Chemistry ◽  
Meta Analysis ◽  
Inflammatory Biomarkers ◽  
Cochrane Library ◽  
Methodologic Quality ◽  
Tnf Α ◽  
Ifn Γ ◽  
Mycoplasma Pneumoniae Pneumonia ◽  
D Dimer

Abstract Objective: To evaluate the discriminative ability of laboratory abnormalities between general mycoplasma pneumoniae pneumonia (GMPP) and refractory MPP (RMPP) in children. Methods: An electronic search in PubMed, Web of Science, Embase, and Cochrane Library was performed to identify studies reporting on laboratory abnormalities in children with GMPP and RMPP. Data were independently extracted by two reviewers. Meta-analyses within the random-effects model were used to synthesize data. Effect sizes were calculated as standardized mean differences (SMD) or weighted mean difference (WMD). The Newcastle-Ottawa Scale (NOS) was used to assess the methodologic quality of included studies. Results: Twenty-one articles (3,877 patients) comparing laboratory findings between patients with GMPP and RMPP were eligible for this meta-analysis. Patients with RMPP had significantly increased neutrophils, CD8+ lymphocytes, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), D-dimer, total IgA, total IgM, as well as decreased lymphocytes, hemoglobin, and albumin. Multiple inflammatory biomarkers (C-reactive protein [CRP], procalcitonin [PCT], erythrocyte sedimentation rate [ESR], ferritin, interleukin [IL]-6, IL-10, IL-17, IL-18, interferon-γ [IFN-γ], and tumor necrosis factor-α [TNF-α]) were also markedly elevated in RMPP patients. Conclusions: Elevated levels of CD8+ lymphocytes, LDH, AST, D-dimer, total IgA, total IgM, inflammatory biomarkers (CRP, PCT, ESR, ferritin, IL-6, IL-10, IL-17, IL-18, IFN-γ, and TNF-α), and lower lymphocytes, hemoglobin, and albumin are associated with RMPP and thus may be used as early identification or even prediction of RMPP in children. Keywords: Child; Refractory Mycoplasma pneumoniae pneumonia; clinical chemistry; meta-analysis

Evaluation of Coagulation and inflammatory Markers in Patients with venous Thromboembolism

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 5131-5131
Author(s):  
Luis Fernando Bittar ◽  
Bruna Mazetto Fonseca ◽  
Fernanda Loureiro de ◽  
Andrade Orsi ◽  
Erich V de Paula ◽  
...  
Keyword(s):  
Risk Factor ◽  
Venous Thromboembolism ◽  
Linear Regression ◽  
Venous Thrombosis ◽  
Inflammatory Markers ◽  
Enzyme Linked Immunosorbent Assay ◽  
Post Thrombotic Syndrome ◽  
Tnf Α ◽  
Significant Difference ◽  
D Dimer

Abstract Abstract 5131 Introduction: Venous thromboembolism (VTE) is a multifactorial disease, and increased levels of coagulation factor VIII (FVIII) has been demonstrated as a risk factor for first and recurrent episodes. Inflammatory processes may play a key role in venous thrombosis by inducing a procoagulant state through the action of cytokines and chemokines on monocytes and endothelial cells. The role of inflammation process in the initiation and evolution of venous thromboembolism is not well understood yet. The aim of the study was to evaluate some coagulation and inflammatory markers in VTE patients. Design and Methods: Between March 2009 and June 2011, 385 consecutive patients with treated VTE were attended at Hematology and Hemotherapy Center of Campinas. The study comprised 71 patients with deep venous thrombosis (DVT) of the lower limbs or pulmonary embolism. We excluded patients with DVT at unusual sites, younger than 18 years old or older than 70 years old, those with cancer, chronic liver, renal or inflammatory disease, antiphospholipid antibody syndrome, natural anticoagulant deficiency. Healthy adult individuals were chosen as controls. FVIII levels (FVIII:C) were measured by a one-stage clotting assay. D-dimer levels were performed by immunoturbidimetric analysis. VWF:Ag, interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor- α (TNF-α) levels were measured by enzyme-linked immunosorbent assay (ELISA). C-reactive protein (CRP) levels were determined by a nephelometric method. The presence of post-thrombotic syndrome (PTS) was evaluated and classified by the Villalta scale. Results: Seventy-one patients with VTE (23M:48F) with a median age of 44 years (range 20–70) were included in the study. The control group consisted of 67 subjects (23M:44F) with a median age of 42 years (range 22–70 years). VTE was spontaneous in 41 (57. 7%) patients and secondary to an acquired risk factor in 42. 3%. Patients with VTE had higher plasma levels of FVIII:C (146. 2 IU/dL vs. 105. 4 IU/dL; p<0. 001), VWF:Ag (150. 3 IU/dL vs. 110. 7 IU/dL; p<0. 001) and D-dimer (0. 46 mg/L vs. 030 mg/L; p<0. 001) compared to controls. Furthermore, the inflammatory markers IL-6 (1. 19 pg/mL vs. 0. 98 pg/mL; p<0. 001) and TNF-α (2. 27 pg/mL vs. 1. 57 pg/mL; p<0. 001) also was higher in patients when compared with controls. No significant difference of CRP and IL-8 levels between patients and controls was observed. Patients with PTS showed higher levels of IL-8 when compared with patients without PTS (23. 03 pg/mL vs. 18. 20 pg/mL; p=0. 04). Patients with moderate or severe PTS (176. 3 IU/dL) showed higher levels of VWF when compared with patients without PTS (137. 8 IU/dL) or mild PTS patients (132. 7 IU/dL); p=0. 04. In a linear regression univariate model, FVIII levels of VTE patients showed association with VWF, D-dimer, IL-6, TNF-α and CRP levels. So, these parameters associated with FVIII were evaluated in a linear regression multivariate model, and VWF and IL-6 levels were independent factors associated with FVIII levels (p<0. 001). Conclusions: Our results show that patients with previous VTE have increased levels of coagulation and inflammatory markers even long time after the acute episode. Moreover, there seems to be a relationship between moderate/severe post-thrombotic syndrome and increased levels of VWF. A possibility is that in moderate and severe PTS, the vascular injury stimulates a increased endothelial cell secretion of VWF. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document